Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo

Chen, Shu-Huey and Hsieh, Yao-Yu and Tzeng, Huey-En and Lin, Chun-Yu and Hsu, Kai-Wen and Chiang, Yun-Shan and Lin, Su-Mei and Su, Ming-Jang and Hsieh, Wen-Shyang and Lee, Chia-Hwa (2020) ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 12 (6). p. 1399. ISSN 2072-6694

Published Version

Download (7MB) | Preview


Chronic myelogenous leukemia (CML) is the most common type of leukemia in adults, and more than 90% of CML patients harbor the abnormal Philadelphia chromosome (Ph) that encodes the BCR-ABL oncoprotein. Although the ABL kinase inhibitor (imatinib) has proven to be very effective in achieving high remission rates and improving prognosis, up to 33% of CML patients still cannot achieve an optimal response. Here, we used CRISPR/Cas9 to specifically target the BCR-ABL junction region in K562 cells, resulting in the inhibition of cancer cell growth and oncogenesis. Due to the variety of BCR-ABL junctions in CML patients, we utilized gene editing of the human ABL gene for clinical applications. Using the ABL gene-edited virus in K562 cells, we detected 41.2% indels in ABL sgRNA_2-infected cells. The ABL-edited cells reveled significant suppression of BCR-ABL protein expression and downstream signals, inhibiting cell growth and increasing cell apoptosis. Next, we introduced the ABL gene-edited virus into a systemic K562 leukemia xenograft mouse model, and bioluminescence imaging of the mice showed a significant reduction in the leukemia cell population in ABL-targeted mice, compared to the scramble sgRNA virus-injected mice. In CML cells from clinical samples, infection with the ABL gene-edited virus resulted in more than 30.9% indels and significant cancer cell death. Notably, no off-target effects or bone marrow cell suppression was found using the ABL gene-edited virus, ensuring both user safety and treatment efficacy. This study demonstrated the critical role of the ABL gene in maintaining CML cell survival and tumorigenicity in vitro and in vivo. ABL gene editing-based therapy might provide a potential strategy for imatinib-insensitive or resistant CML patients


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Chen, Shu-Huey
Hsieh, Yao-Yu
Tzeng, Huey-En
Lin, Chun-Yu
Hsu, Kai-Wen
Chiang, Yun-Shanyuc114@pitt.eduyuc114
Lin, Su-Mei
Su, Ming-Jang
Hsieh, Wen-Shyang
Lee, Chia-Hwa
Date: 26 May 2020
Date Type: Publication
Journal or Publication Title: Cancers
Volume: 12
Number: 6
Publisher: MDPI AG
Page Range: p. 1399
DOI or Unique Handle: 10.3390/cancers12061399
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Refereed: Yes
Uncontrolled Keywords: CRISPR/Cas9, gene edit, Philadelphia chromosome, BCR-ABL, CML
ISSN: 2072-6694
Official URL:
Funders: Ministry of Science and Technology, Shuang Ho Hospital, Drug Development Center, China Medical University” from The Featured Areas Research Center Program with in the frame work of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan
Article Type: Research Article
Date Deposited: 11 Jun 2021 19:14
Last Modified: 11 Jun 2021 19:16


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item